Septerna (NASDAQ:SEPN) SVP Sells $114,521.88 in Stock

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 3,333 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $34.36, for a total value of $114,521.88. Following the completion of the transaction, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,312,716.32. The trade was a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Septerna Stock Performance

NASDAQ:SEPN opened at $34.00 on Friday. The business’s fifty day moving average is $30.06 and its 200 day moving average is $27.65. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -41.97 and a beta of 2.29. Septerna, Inc. has a 52-week low of $10.62 and a 52-week high of $37.99.

Septerna (NASDAQ:SEPN) last issued its earnings results on Monday, May 11th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.23. The business had revenue of $26.52 million during the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%. Equities analysts predict that Septerna, Inc. will post -1.59 EPS for the current fiscal year.

Analyst Ratings Changes

SEPN has been the subject of several recent analyst reports. Raymond James Financial boosted their price objective on shares of Septerna from $47.00 to $53.00 and gave the company a “strong-buy” rating in a research note on Monday, June 8th. Guggenheim cut their price target on shares of Septerna from $52.00 to $45.00 and set a “buy” rating for the company in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Septerna in a research report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $60.00 price objective on shares of Septerna in a research report on Tuesday, March 10th. Finally, Wall Street Zen lowered Septerna from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $45.89.

Institutional Investors Weigh In On Septerna

Hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. grew its stake in Septerna by 86.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock worth $75,698,000 after buying an additional 1,260,409 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Septerna during the 1st quarter worth $21,334,000. First Light Asset Management LLC bought a new stake in shares of Septerna during the 4th quarter worth $17,308,000. Primecap Management Co. CA purchased a new position in Septerna in the fourth quarter worth $15,225,000. Finally, Perceptive Advisors LLC purchased a new position in Septerna in the second quarter worth $5,723,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.